A New Coronavirus Variant Is Spreading in New York
Post# of 154810
(Total Views: 397)
Posted On: 02/25/2021 12:07:37 PM
A New Coronavirus Variant Is Spreading in New York
Article appeared in NYT yesterday. More concern from researchers that some variants are less susceptible to vaccines. Also, the longer the virus circulates, the longer it will take to get herd immunity.
Link and excerpts below.
https://www.nytimes.com/2021/02/24/health/cor...d99674116f
A new form of the coronavirus is spreading rapidly in New York City, and it carries a worrisome mutation that may weaken the effectiveness of vaccines, two teams of researchers have found.
The new variant, called B.1.526, first appeared in samples collected in the city in November. By the middle of this month, it accounted for about one in four viral sequences appearing in a database shared by scientists.
Dr. Nussenzweig said he was more worried about the variant in New York than the one quickly spreading in California. Yet another contagious new variant, discovered in Britain, now accounts for about 2,000 cases in 45 states. It is expected to become the most prevalent form of the coronavirus in the United States by the end of March.
The Caltech researchers discovered the rise in B.1.526 by scanning for mutations in hundreds of thousands of viral genetic sequences in a database called GISAID. “There was a pattern that was recurring, and a group of isolates concentrated in the New York region that I hadn’t seen,” said Anthony West, a computational biologist at Caltech.
He and his colleagues found two versions of the coronavirus increasing in frequency: one with the E484K mutation seen in South Africa and Brazil, which is thought to help the virus partially dodge the vaccines; and another with a mutation called S477N, which may affect how tightly the virus binds to human cells.
By mid-February, the two together accounted for about 27 percent of New York City viral sequences deposited into the database, Dr. West said. (For the moment, both are grouped together as B.1.526.)
Patients infected with virus carrying that mutation were about six years older on average and more likely to have been hospitalized.
The team also identified six cases of the variant that pummeled Britain, two infections with a variant identified in Brazil, and one case of the variant that took over in South Africa. The latter two had not been reported in New York City before, Dr. Ho said.
The E484K mutation has independently cropped up in many different parts of the world, an indication that it offers the virus a significant advantage.
“Variants that have an advantage are going to rise pretty fast in frequency, especially when numbers are coming down over all,” said Andrew Read, an evolutionary microbiologist at Penn State University.
Dr. Ho's team reported in January that the monoclonal antibodies made by Eli Lilly, and one of the monoclonal antibodies in a cocktail made by Regeneron, are powerless against the variant identified in South Africa.
And several studies have now shown that variants containing the E484K mutation are less susceptible to the vaccines than was the original form of the virus. The mutation interferes with the activity of a class of antibodies that nearly everyone makes, Dr. Nussenzweig said.
Article appeared in NYT yesterday. More concern from researchers that some variants are less susceptible to vaccines. Also, the longer the virus circulates, the longer it will take to get herd immunity.
Link and excerpts below.
https://www.nytimes.com/2021/02/24/health/cor...d99674116f
A new form of the coronavirus is spreading rapidly in New York City, and it carries a worrisome mutation that may weaken the effectiveness of vaccines, two teams of researchers have found.
The new variant, called B.1.526, first appeared in samples collected in the city in November. By the middle of this month, it accounted for about one in four viral sequences appearing in a database shared by scientists.
Dr. Nussenzweig said he was more worried about the variant in New York than the one quickly spreading in California. Yet another contagious new variant, discovered in Britain, now accounts for about 2,000 cases in 45 states. It is expected to become the most prevalent form of the coronavirus in the United States by the end of March.
The Caltech researchers discovered the rise in B.1.526 by scanning for mutations in hundreds of thousands of viral genetic sequences in a database called GISAID. “There was a pattern that was recurring, and a group of isolates concentrated in the New York region that I hadn’t seen,” said Anthony West, a computational biologist at Caltech.
He and his colleagues found two versions of the coronavirus increasing in frequency: one with the E484K mutation seen in South Africa and Brazil, which is thought to help the virus partially dodge the vaccines; and another with a mutation called S477N, which may affect how tightly the virus binds to human cells.
By mid-February, the two together accounted for about 27 percent of New York City viral sequences deposited into the database, Dr. West said. (For the moment, both are grouped together as B.1.526.)
Patients infected with virus carrying that mutation were about six years older on average and more likely to have been hospitalized.
The team also identified six cases of the variant that pummeled Britain, two infections with a variant identified in Brazil, and one case of the variant that took over in South Africa. The latter two had not been reported in New York City before, Dr. Ho said.
The E484K mutation has independently cropped up in many different parts of the world, an indication that it offers the virus a significant advantage.
“Variants that have an advantage are going to rise pretty fast in frequency, especially when numbers are coming down over all,” said Andrew Read, an evolutionary microbiologist at Penn State University.
Dr. Ho's team reported in January that the monoclonal antibodies made by Eli Lilly, and one of the monoclonal antibodies in a cocktail made by Regeneron, are powerless against the variant identified in South Africa.
And several studies have now shown that variants containing the E484K mutation are less susceptible to the vaccines than was the original form of the virus. The mutation interferes with the activity of a class of antibodies that nearly everyone makes, Dr. Nussenzweig said.
(1)
(0)